Report
Patrik Ling
EUR 434.26 For Business Accounts Only

Wilson Therapeutics (Buy, TP: SEK195.00) - First patient included in FOCuS

Wilson Therapeutics’ reported Q4 earnings loss was in line with our expectations and, in our view, the Q4 report was a non-event. The next potential catalyst for the share should be the upcoming CMD in March and the announcement that the pivotal phase III trial (FOCuS) has completed enrolment (we expect this in mid-2018). We reiterate our BUY recommendation and SEK195 target price.
Underlying
Wilson Therapeutics AB

Wilson Therapeutics AB is a Sweden-based biopharmaceutical company that is active in the development of a treatment for Wilson disease. Wilson disease is a genetic disease that causes copper poisoning. The Company's main product is Decuprate (tetrathiomolybdate), a de-coppering agent with a mechanism of action enabling it to bind copper to restore, in part or in whole, the body's own buffer system for copper in the liver. Decuprate also restores the natural excretion route via the bile rather than preventing copper to be absorbed or excreted through the kidneys. The Company operates through the Swedish subsidiaries Wilson Therapeutics Incentive AB and TTM Europe Development AB, as well as through Wilson Therapeutics Inc, a subsidiary based in the United States.

Provider
DnB Markets
DnB Markets

DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.

 

Analysts
Patrik Ling

Other Reports on these Companies
Other Reports from DnB Markets

ResearchPool Subscriptions

Get the most out of your insights

Get in touch